Hypera (HYPE9) Stock Overview

Operates as a pharmaceutical company in Brazil. More details

HYPE9 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	4/6
Past Performance	1/6
Financial Health	2/6
Dividends	4/6

Rewards

Trading at 50.5% below our estimate of its fair value

Earnings are forecast to grow 23.61% per year

Risk Analysis

Interest payments are not well covered by earnings

Shares are highly illiquid

Unstable dividend track record

HYPE9 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

UNCYFeatured

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.

View narrative

stuart_roberts

Community Contributor

US$21.53FV • 69.4% undervalued

5419.8%Revenue growth p.a.

5.3k

105

2mo ago

Hypera S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Hypera
Historical stock prices
Current Share Price	R$24.19
52 Week High	R$25.00
52 Week Low	R$21.55
Beta	0.20
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	7.99%

Recent updates

Shareholder Returns

	HYPE9	BR Pharmaceuticals	BR Market
7D	3.4%	0.5%	1.0%
1Y	n/a	0.9%	27.6%

Return vs Industry: Insufficient data to determine how HYPE9 performed against the BR Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how HYPE9 performed against the BR Market.

Price Volatility

Is HYPE9's price volatile compared to industry and market?
HYPE9 volatility
HYPE9 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.0%
Market Average Movement	4.8%
10% most volatile stocks in BR Market	8.9%
10% least volatile stocks in BR Market	1.7%

Stable Share Price: HYPE9's share price has been volatile over the past 3 months compared to the BR market.

Volatility Over Time: Insufficient data to determine HYPE9's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1999	10,564	Breno Pires de Oliveira	www.hypera.com.br

Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptics products under Merthiolate brand; Herbal medicine products under Maracugina, Eparema, Tamarine, and Naturetti brands; gastrointestinal products under Dramin, Estomazil, Engov, Lacto-purga, gastrol, Epocler, Bifilax, and Pepsamar brands.

Hypera S.A. Fundamentals Summary

How do Hypera's earnings and revenue compare to its market cap?
HYPE9 fundamental statistics
Market cap	R$14.74b
Earnings (TTM)	R$1.20b
Revenue (TTM)	R$7.70b

12.3x

P/E Ratio

1.9x

P/S Ratio

Is HYPE9 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HYPE9 income statement (TTM)
Revenue	R$7.70b
Cost of Revenue	R$3.15b
Gross Profit	R$4.55b
Other Expenses	R$3.35b
Earnings	R$1.20b

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

Apr 28, 2026

Earnings per share (EPS)	1.89
Gross Margin	59.04%
Net Profit Margin	15.53%
Debt/Equity Ratio	74.6%

How did HYPE9 perform over the long term?

See historical performance and comparison

Dividends

5.0%

Current Dividend Yield

62%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/04/01 05:19
End of Day Share Price	2026/03/31 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hypera S.A. is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Andréa Aznar	BB Banco de Investimento S.A.
Robert Ford Aguilar	BofA Global Research
Marcio Osako	Bradesco S.A. Corretora de Títulos e Valores Mobiliários

Hypera S.A.BOVESPA:HYPE9 Stock Report